Your browser doesn't support javascript.
loading
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin, U; Türeci, Ö; Manikhas, G; Lordick, F; Rusyn, A; Vynnychenko, I; Dudov, A; Bazin, I; Bondarenko, I; Melichar, B; Dhaene, K; Wiechen, K; Huber, C; Maurus, D; Arozullah, A; Park, J W; Schuler, M; Al-Batran, S-E.
Afiliação
  • Sahin U; Department of Experimental and Translational Oncology, TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Department of Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Biopharmaceu
  • Türeci Ö; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany; CI3 - Cluster of Individualized Immune Intervention, Mainz, Germany; formerly of Ganymed Pharmaceuticals GmbH.
  • Manikhas G; Department of Oncology, City Clinical Oncology Center, St. Petersburg, Russia.
  • Lordick F; Department of Medicine II and University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, Germany.
  • Rusyn A; Department of Oncology, Transcarpathian Regional Clinical Oncological Center, Uzhhorod, Ukraine.
  • Vynnychenko I; Sumy State University, Sumy Regional Clinical Oncology Center, Oncothoracic Department, Sumy, Ukraine.
  • Dudov A; Department of Oncology, Acibadem City Clinic Mladost, Sofia, Bulgaria.
  • Bazin I; Department of Clinical Pharmacology and Chemotherapy, Russian Oncology Research Center n. a. N.N. Blokhin, Moscow, Russia.
  • Bondarenko I; Dnipropetrovsk Medical Academy, City Multispecialty Clinical Hospital #4, Department of Chemotherapy, Dnipropetrovsk, Ukraine.
  • Melichar B; Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
  • Dhaene K; MD Dhaene Pathology Lab BVBA, Destelbergen, Belgium.
  • Wiechen K; Department of Pathology, Klinikum Worms GmbH, Institute for Pathology, Worms, Germany.
  • Huber C; Department of Experimental and Translational Oncology, TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany; CI3 - Cluster of Individualized Immune Interven
  • Maurus D; Formerly of Ganymed Pharmaceuticals GmbH, Mainz, Germany.
  • Arozullah A; Astellas Pharma Global Development, Inc., Northbrook, USA.
  • Park JW; Astellas Pharma Global Development, Inc., Northbrook, USA.
  • Schuler M; West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
  • Al-Batran SE; Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, Frankfurt, Germany. Electronic address: albatran.salah@khnw.de.
Ann Oncol ; 32(5): 609-619, 2021 05.
Article em En | MEDLINE | ID: mdl-33610734
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article